(i) Philogen will give a poster presentation about the phase II study of Daromun (Nidlegy) for the treatment of non-melanoma skin cancer -

(ii) Study shows promising early signs of efficacy in patients with basal cell carcinoma

Nidlegy was found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to continue the study as planned.

Bostel Technologies has published a clinical research study on artificial intelligence telemedicine that identifies skin cancer.

No-cost online lessons have saved lives of students, teachers and their family members

The Sunface App photoages the users skin based on skin type and individual UV-protection behavior.

Spot It, Check It!

For centuries pathologists have relied on the microscopic examination of tumors to distinguish between atypical moles and melanoma. By analyzing the level of proteins within mole cells, mass spectrometry can aid in the diagnosis of atypical moles. In this study, mass spectrometry correlated better than the gold standard of histologic examination to determine if an atypical mole was in fact benign or a melanoma. Early diagnosis of melanoma is critical to cure and long term survival.

Highlands Oncology Group Physician Will Have New Abstracts Released at International Congress of the Society for Melanoma Research in Zurich.

Dr. J. Thaddeus Beck, of Highlands Oncology Group (HOG), will be conducting a clinical trial testing treatments for patients with melanoma carrying the NRAS mutation

Texas becomes fifth state to enact an under-18 tanning ban

Return reflects challenges in treatment of solid tumor cancers and the need for better therapeutic delivery.

Nevada becomes fourth state to enact an under-18 tanning ban

The inaugural AIM for the CURE Melanoma Walk in Fullerton will raise funds to support research for the CURE of melanoma on May 12

Accurate knowledge is key for prevention, detection and also treatment.

San Diego-based OncoSec Medical Inc. among those who are looking at novel approaches.

Melanoma, like many other modern diseases, had previously been considered an age related condition.

Health Discovery Corporation, developers of MelApp, reports great adoption among consumers with nearly 5,000 downloads across 48 countries in just its first 2 months. Pleased with the interest, the company will launch MelApp for Android in October.

Jeffrey S. Weber, MD, PhD, of the H. Lee Moffitt Cancer Center leads a 1-day conference to provide clinicians with an update on the science of melanoma, pertinent clinical trial information, investigational agents, and their unusual adverse effects.

Christos Prevezas Software released a new dermatology software application that enables dermatologists
to make a body mole mapping of their patients , monitor their skin lesions and assist in the diagnosis of melanoma and other types of cancer.

Today marks a major advance in the fight against skin cancer, as the U.S. Food and Drug Administration (FDA) approved a new immune-based therapy for the treatment of melanoma, the leading cause of death from skin cancer.

IMER, an oncology continuing education company, will offer a free live webcast on advanced melanoma. This unique event is part of the 6 symposia series IMER will offer during the ONS 36th Annual Congress in Boston.

Immunotherapy made a giant leap forward this weekend with the release of clinical trial results of BMS's ipilimumab. The results indicate that ipilimumab significantly improved the survival of patients with late stage melanoma.

With May being Skin Cancer Awareness Month, it is good time for golfers to learn how to protect themselves in the sun and to schedule an exam to see what sun damage they may have incurred.